ClinicalTrials.gg
CompletedNCT05061693Updated Jul 11, 2025Results posted

A Study to Evaluate the Efficacy and Safety of INCB054707 in Participants With Prurigo Nodularis

A Phase 2 interventional study of INCB054707 and Placebo in Prurigo Nodularis, sponsored by Incyte Corporation. Completed at 49 sites in 6 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-07-11.

Sponsored by Incyte Corporation · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
146
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 23 studies in Prurigo with a site in United States — 4 open to participants now, 8 under way, 4 of them phase 3. Prurigo · United States.

Enrollment
10th of 21
146 · median 140
Started
2021
with 2 others
Phase 2
5 of 23
2 open now
Registered
10th of 23
by date
Lead sponsor
6 of 23
Incyte Corporation

Among the 23 studies in Prurigo with a site in United States, this one is the 10th largest by enrollment of the 21 interventional ones that give a count, is one of 3 that started in 2021, is one of 5 in phase 2, and was the 10th registered.

Prurigo

38 studies on the registry are indexed under Prurigo; 10 are open to participants now.

Browse Prurigo studies →

Open to participants now

4 of the 23 studies in Prurigo with a site in United States are open now. Recruiting first, the newest first:

All 4 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 7 Prurigo studies recruiting now, 4 set no upper age limit and 2 stop at 75 or younger; 2 take children under 18; none take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 23 studies in Prurigo with a site in United States, or all of them as a file.
02

Study summary

The purpose of this study is to evaluate the efficacy and safety of INCB054707 in participants with prurigo nodularis over a 16-week double-blind placebo-controlled treatment period, followed by a 24 -week single blind extension period.

03

Conditions studied

  • Prurigo Nodularis

Browse trials for

Keywords

  • Prurigo nodularis
  • PN
  • INCB054707
  • chronic pruritus
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Clinical diagnosis of PN for at least 3 months before screening.
  • Inadequate response or intolerant to ongoing or prior PN therapy.
  • ≥ 20 pruriginous lesions on ≥ 2 different body regions at screening and Day 1.
  • Willingness to avoid pregnancy or fathering children
  • Further inclusion criteria apply.

Exclusion criteria

Exclusion Criteria:

  • Have chronic pruritus due to a condition other than PN; have neuropathic and psychogenic pruritus such as but not limited to notalgia paresthetica, brachioradial pruritus, small fiber neuropathy, skin picking syndrome, or delusional parasitosis.
  • Current use of a medication known to cause pruritus.
  • Women who are pregnant (or who are considering pregnancy) or lactating.
  • Medical history including thrombocytopenia, coagulopathy or dysfunction, Q-wave interval abnormalities, current or history of certain infections, cancer, lymphoproliferative disorders and other medical conditions at the discretion of the investigator.
  • Have evidence of active or latent or inadequately treated infection with Mycobacterium tuberculosis.
  • Participants known to be infected with , , or .
  • Laboratory values outside of the protocol-defined ranges.
  • Further exclusion criteria apply.
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Investigator, Outcomes assessor)
Enrollment
146 participants (actual)

Study arms

  • Experimental
    INCB054707 Dose A

    Participants will receive INCB054707 Dose A for 16 weeks (Period 1), followed by INCB054707 Dose B (responders) or by INCB054707 Dose C (partial or nonresponders) for 24 weeks (Period 2).

    Drug: INCB054707

  • Experimental
    INCB054707 Dose B

    Participants will receive INCB054707 Dose B for 16 weeks (Period 1), followed by INCB054707 Dose B (responders) or by INCB054707 Dose C (partial or nonresponders) for 24 weeks (Period 2).

    Drug: INCB054707

  • Experimental
    INCB054707 Dose C

    Participants will receive INCB054707 Dose C for 16 weeks (Period 1), followed by INCB054707 Dose B (responders) or by INCB054707 Dose C (partial or nonresponders) for 24 weeks (Period 2).

    Drug: INCB054707

  • Placebo comparator
    Placebo followed by INCB054707 Dose B or C

    Participants will receive placebo for 16 weeks (Period 1), followed by INCB054707 Dose B (responders) or by INCB054707 Dose C (partial or nonresponders) for 24 weeks (Period 2).

    Drug: Placebo

Interventions

  • Oral; Tablet

    Also known as: Povorcitinib

  • DrugPlacebo

    Oral; Tablet

06

What researchers measure

Primary outcomes

  1. Percentage of Participants Achieving ≥4-point Improvement in Itch Numerical Rating Scale (NRS) Score at Week 16

    Each evening, the participants assessed their worst level of itch during the past 24 hours on a scale of 0 (no itch) to 10 (worst itch imaginable). The Baseline Itch NRS score was determined by averaging the 7 daily Itch NRS scores before Day 1 (i.e., Day -7 to Day -1). If ≥4 of the 7 days of the daily Itch NRS scores were missing prior to Day 1, then the Baseline Itch NRS score was set to "missing." The by-visit Itch NRS score for postbaseline visits was determined by averaging the 7 daily Itch NRS scores before the visit day. If 4 or more daily Itch NRS scores out of the 7 days before the visit day were missing, the Itch NRS score at the visit was set to missing.

    Time frame: Baseline; Week 16

Secondary outcomes

  1. Percentage of Participants Achieving Investigator's Global Assessment-Treatment Success (IGA-TS) (IGA Score of 0 or 1 With a ≥2-grade Improvement From Baseline) at Week 16

    The IGA for chronic prurigo considers the number of pruriginous lesions, which includes papules, nodules, plaques, umbilicated ulcers, and ulcers, and uses them as an overall severity rating on a scale of 0 to 4. 0: clear; no pruriginous lesions (0 lesions). 1: almost clear; rare palpable pruriginous lesions (approximately 1-5 lesions). 2: mild; few palpable pruriginous lesions (approximately 6-19 lesions). 3: moderate: many palpable pruriginous lesions (approximately 20-100 lesions). 4: severe; abundant palpable pruriginous lesions (over 100 lesions). The IGA-TS is defined as an IGA score of 0 or 1 with a ≥2-grade improvement from Baseline.

    Time frame: Baseline; Week 16

  2. Time to ≥4-point Improvement From Baseline in Itch NRS Score

    Each evening, the participants assessed their worst level of itch during the past 24 hours on a scale of 0 (no itch) to 10 (worst itch imaginable). The Baseline Itch NRS score was determined by averaging the 7 daily Itch NRS scores before Day 1 (i.e., Day -7 to Day -1). If ≥4 of the 7 days of the daily Itch NRS scores were missing prior to Day 1, then the Baseline Itch NRS score was set to "missing." The by-visit Itch NRS score for postbaseline visits was determined by averaging the 7 daily Itch NRS scores before the visit day. If 4 or more daily Itch NRS scores out of the 7 days before the visit day were missing, the Itch NRS score at the visit was set to missing.

    Time frame: up to 122 days

  3. PC Period: Number of Participants With Any Treatment-emergent Adverse Event (TEAE)

    An adverse event (AE) is any untoward medical occurrence associated with the use of a drug in humans, whether or not it is considered drug related. An AE can therefore be any unfavorable or unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of study drug. A TEAE is any AE either reported for the first time or the worsening of a pre-existing event after the first dose of study drug up to 30 days after the last dose of study drug.

    Time frame: up to 152 days

  4. PC Period: Number of Participants With Any ≥Grade 3 TEAE

    A TEAE is any AE either reported for the first time or the worsening of a pre-existing event after the first dose of study drug up to 30 days after the last dose of study drug. The severity of AEs was assessed using Common Terminology Criteria for Adverse Events version 5.0 Grades 1 through 5. The investigator made an assessment of intensity for each AE and serious adverse event (SAE) reported during the study and assigned it to 1 of the following categories. Grade 1: mild; asymptomatic or mild symptoms; clinical or diagnostic observations only; treatment not indicated. Grade 2: moderate; minimal, local, or noninvasive treatment indicated; limiting age-appropriate activities of daily living. Grade 3: severe or medically significant but not immediately life-threatening; hospitalization or prolongation of hospitalization indicated; disabling; limiting self-care activities of daily living. Grade 4: life-threatening consequences; urgent treatment indicated. Grade 5: fatal.

    Time frame: up to 152 days

  5. Extension Period: Number of Participants With Any TEAE

    An AE is any untoward medical occurrence associated with the use of a drug in humans, whether or not it is considered drug related. An AE can therefore be any unfavorable or unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of study drug. A TEAE is any AE either reported for the first time or the worsening of a pre-existing event after the first dose of study drug up to 30 days after the last dose of study drug.

    Time frame: up to 215 days

  6. Extension Period: Number of Participants With Any ≥Grade 3 TEAE

    A TEAE is any AE either reported for the first time or the worsening of a pre-existing event after the first dose of study drug up to 30 days after the last dose of study drug. The severity of AEs was assessed using Common Terminology Criteria for Adverse Events version 5.0 Grades 1 through 5. The investigator made an assessment of intensity for each AE and serious adverse event (SAE) reported during the study and assigned it to 1 of the following categories. Grade 1: mild; asymptomatic or mild symptoms; clinical or diagnostic observations only; treatment not indicated. Grade 2: moderate; minimal, local, or noninvasive treatment indicated; limiting age-appropriate activities of daily living. Grade 3: severe or medically significant but not immediately life-threatening; hospitalization or prolongation of hospitalization indicated; disabling; limiting self-care activities of daily living. Grade 4: life-threatening consequences; urgent treatment indicated. Grade 5: fatal.

    Time frame: up to 215 days

07

Results

Posted Aug 27, 2024

Participant flow

16-week Placebo-controlled (PC) Period
Participant flow — 16-week Placebo-controlled (PC) Period
MilestonePC Period: PlaceboPC Period: Povorcitinib 15 mgPC Period: Povorcitinib 45 mgPC Period: Povorcitinib 75 mgExtension Period: Placebo to Povorcitinib 45 mgExtension Period: Povorcitinib 15 mg to 45 mgExtension Period: Povorcitinib 45 mg to 45 mgExtension Period: Povorcitinib 75 mg to 45 mgExtension Period: Placebo to Povorcitinib 75 mgExtension Period: Povorcitinib 15 mg to 75 mgExtension Period: Povorcitinib 45 mg to 75 mgExtension Period: Povorcitinib 75 mg to 75 mg
Started3736363700000000
Completed3229313300000000
Not completed575400000000
Withdrew: Adverse event111000000000
Withdrew: Death010000000000
Withdrew: Lack of efficacy100000000000
Withdrew: Lost to follow-up001000000000
Withdrew: Protocol violation111200000000
Withdrew: Withdrawal by subject242200000000
24-week Extension Period
Participant flow — 24-week Extension Period
MilestonePC Period: PlaceboPC Period: Povorcitinib 15 mgPC Period: Povorcitinib 45 mgPC Period: Povorcitinib 75 mgExtension Period: Placebo to Povorcitinib 45 mgExtension Period: Povorcitinib 15 mg to 45 mgExtension Period: Povorcitinib 45 mg to 45 mgExtension Period: Povorcitinib 75 mg to 45 mgExtension Period: Placebo to Povorcitinib 75 mgExtension Period: Povorcitinib 15 mg to 75 mgExtension Period: Povorcitinib 45 mg to 75 mgExtension Period: Povorcitinib 75 mg to 75 mg
Started00001481530252318
Completed00001471225221813
Not completed000000135355
Withdrew: Adverse event000000022013
Withdrew: Lack of efficacy000000000020
Withdrew: Lost to follow-up000000101100
Withdrew: Withdrawal by subject000000001221
Withdrew: Sponsor decision000000010000
Withdrew: Site closure000000001001

Outcome measures

PrimaryPercentage of Participants Achieving ≥4-point Improvement in Itch Numerical Rating Scale (NRS) Score at Week 16

Each evening, the participants assessed their worst level of itch during the past 24 hours on a scale of 0 (no itch) to 10 (worst itch imaginable). The Baseline Itch NRS score was determined by averaging the 7 daily Itch NRS scores before Day 1 (i.e., Day -7 to Day -1). If ≥4 of the 7 days of the daily Itch NRS scores were missing prior to Day 1, then the Baseline Itch NRS score was set to "missing." The by-visit Itch NRS score for postbaseline visits was determined by averaging the 7 daily Itch NRS scores before the visit day. If 4 or more daily Itch NRS scores out of the 7 days before the visit day were missing, the Itch NRS score at the visit was set to missing.

Time frame:
Baseline; Week 16
Reported as:
Number · percentage of participants
Percentage of Participants Achieving ≥4-point Improvement in Itch Numerical Rating Scale (NRS) Score at Week 16
percentage of participantsPlaceboPovorcitinib 15 mgPovorcitinib 45 mgPovorcitinib 75 mg
Percentage of Participants Achieving ≥4-point Improvement in Itch Numerical Rating Scale (NRS) Score at Week 168.1 (1.7 to 21.9)36.1 (20.8 to 53.8)44.4 (27.9 to 61.9)56.8 (39.5 to 72.9)
Statistical analysis
  • Placebo vs Povorcitinib 15 mg · Regression, Logistic · p = 0.0061 · Odds ratio (or): 7.1 · 95% CI 1.6 to 45.4Exact Logistic regression: (response at Week 16 = treatment + stratification factor \[Day 1 Investigator's Global Assessment score (3 or 4)\])
  • Placebo vs Povorcitinib 15 mg · Difference in response rate: 28.0The standard error of the difference between response rates was from normal approximation.
  • Placebo vs Povorcitinib 45 mg · Regression, Logistic · p = 0.0005 · Odds ratio (or): 10.2 · 95% CI 2.3 to 65.6Exact Logistic regression: (response at Week 16 = treatment + stratification factor \[Day 1 Investigator's Global Assessment score (3 or 4)\])
  • Placebo vs Povorcitinib 45 mg · Difference in response rate: 36.3The standard error of the difference between response rates was from normal approximation.
  • Placebo vs Povorcitinib 75 mg · Regression, Logistic · p = <0.0001 · Odds ratio (or): 16.8 · 95% CI 3.9 to 107.5Exact Logistic regression: (response at Week 16 = treatment + stratification factor \[Day 1 Investigator's Global Assessment score (3 or 4)\])
  • Placebo vs Povorcitinib 75 mg · Difference in response rate: 48.6The standard error of the difference between response rates was from normal approximation.
SecondaryPercentage of Participants Achieving Investigator's Global Assessment-Treatment Success (IGA-TS) (IGA Score of 0 or 1 With a ≥2-grade Improvement From Baseline) at Week 16

The IGA for chronic prurigo considers the number of pruriginous lesions, which includes papules, nodules, plaques, umbilicated ulcers, and ulcers, and uses them as an overall severity rating on a scale of 0 to 4. 0: clear; no pruriginous lesions (0 lesions). 1: almost clear; rare palpable pruriginous lesions (approximately 1-5 lesions). 2: mild; few palpable pruriginous lesions (approximately 6-19 lesions). 3: moderate: many palpable pruriginous lesions (approximately 20-100 lesions). 4: severe; abundant palpable pruriginous lesions (over 100 lesions). The IGA-TS is defined as an IGA score of 0 or 1 with a ≥2-grade improvement from Baseline.

Time frame:
Baseline; Week 16
Reported as:
Number · percentage of participants
Percentage of Participants Achieving Investigator's Global Assessment-Treatment Success (IGA-TS) (IGA Score of 0 or 1 With a ≥2-grade Improvement From Baseline) at Week 16
percentage of participantsPlaceboPovorcitinib 15 mgPovorcitinib 45 mgPovorcitinib 75 mg
Percentage of Participants Achieving Investigator's Global Assessment-Treatment Success (IGA-TS) (IGA Score of 0 or 1 With a ≥2-grade Improvement From Baseline) at Week 165.4 (0.7 to 18.2)13.9 (4.7 to 29.5)30.6 (16.3 to 48.1)48.6 (31.9 to 65.6)
SecondaryTime to ≥4-point Improvement From Baseline in Itch NRS Score

Each evening, the participants assessed their worst level of itch during the past 24 hours on a scale of 0 (no itch) to 10 (worst itch imaginable). The Baseline Itch NRS score was determined by averaging the 7 daily Itch NRS scores before Day 1 (i.e., Day -7 to Day -1). If ≥4 of the 7 days of the daily Itch NRS scores were missing prior to Day 1, then the Baseline Itch NRS score was set to "missing." The by-visit Itch NRS score for postbaseline visits was determined by averaging the 7 daily Itch NRS scores before the visit day. If 4 or more daily Itch NRS scores out of the 7 days before the visit day were missing, the Itch NRS score at the visit was set to missing.

Time frame:
up to 122 days
Reported as:
Median · days
Time to ≥4-point Improvement From Baseline in Itch NRS Score
daysPlaceboPovorcitinib 15 mgPovorcitinib 45 mgPovorcitinib 75 mg
Time to ≥4-point Improvement From Baseline in Itch NRS ScoreNA (NA to NA)58.0 (16.0 to NA)35.0 (21.0 to NA)19.0 (13.0 to 47.0)
SecondaryPC Period: Number of Participants With Any Treatment-emergent Adverse Event (TEAE)

An adverse event (AE) is any untoward medical occurrence associated with the use of a drug in humans, whether or not it is considered drug related. An AE can therefore be any unfavorable or unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of study drug. A TEAE is any AE either reported for the first time or the worsening of a pre-existing event after the first dose of study drug up to 30 days after the last dose of study drug.

Time frame:
up to 152 days
Reported as:
Count of participants · Participants
PC Period: Number of Participants With Any Treatment-emergent Adverse Event (TEAE)
ParticipantsPlaceboPovorcitinib 15 mgPovorcitinib 45 mgPovorcitinib 75 mg
PC Period: Number of Participants With Any Treatment-emergent Adverse Event (TEAE)20202528
SecondaryPC Period: Number of Participants With Any ≥Grade 3 TEAE

A TEAE is any AE either reported for the first time or the worsening of a pre-existing event after the first dose of study drug up to 30 days after the last dose of study drug. The severity of AEs was assessed using Common Terminology Criteria for Adverse Events version 5.0 Grades 1 through 5. The investigator made an assessment of intensity for each AE and serious adverse event (SAE) reported during the study and assigned it to 1 of the following categories. Grade 1: mild; asymptomatic or mild symptoms; clinical or diagnostic observations only; treatment not indicated. Grade 2: moderate; minimal, local, or noninvasive treatment indicated; limiting age-appropriate activities of daily living. Grade 3: severe or medically significant but not immediately life-threatening; hospitalization or prolongation of hospitalization indicated; disabling; limiting self-care activities of daily living. Grade 4: life-threatening consequences; urgent treatment indicated. Grade 5: fatal.

Time frame:
up to 152 days
Reported as:
Count of participants · Participants
PC Period: Number of Participants With Any ≥Grade 3 TEAE
ParticipantsPlaceboPovorcitinib 15 mgPovorcitinib 45 mgPovorcitinib 75 mg
PC Period: Number of Participants With Any ≥Grade 3 TEAE0112
SecondaryExtension Period: Number of Participants With Any TEAE

An AE is any untoward medical occurrence associated with the use of a drug in humans, whether or not it is considered drug related. An AE can therefore be any unfavorable or unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of study drug. A TEAE is any AE either reported for the first time or the worsening of a pre-existing event after the first dose of study drug up to 30 days after the last dose of study drug.

Time frame:
up to 215 days
Reported as:
Count of participants · Participants
Extension Period: Number of Participants With Any TEAE
ParticipantsPlacebo to Povorcitinib 45 mgPovorcitinib 15 mg to 45 mgPovorcitinib 45 mgPovorcitinib 75 mg to 45 mgPlacebo to Povorcitinib 75 mgPovorcitinib 15 mg to 75 mgPovorcitinib 45 mg to 75 mgPovorcitinib 75 mg
Extension Period: Number of Participants With Any TEAE035720191613
SecondaryExtension Period: Number of Participants With Any ≥Grade 3 TEAE

A TEAE is any AE either reported for the first time or the worsening of a pre-existing event after the first dose of study drug up to 30 days after the last dose of study drug. The severity of AEs was assessed using Common Terminology Criteria for Adverse Events version 5.0 Grades 1 through 5. The investigator made an assessment of intensity for each AE and serious adverse event (SAE) reported during the study and assigned it to 1 of the following categories. Grade 1: mild; asymptomatic or mild symptoms; clinical or diagnostic observations only; treatment not indicated. Grade 2: moderate; minimal, local, or noninvasive treatment indicated; limiting age-appropriate activities of daily living. Grade 3: severe or medically significant but not immediately life-threatening; hospitalization or prolongation of hospitalization indicated; disabling; limiting self-care activities of daily living. Grade 4: life-threatening consequences; urgent treatment indicated. Grade 5: fatal.

Time frame:
up to 215 days
Reported as:
Count of participants · Participants
Extension Period: Number of Participants With Any ≥Grade 3 TEAE
ParticipantsPlacebo to Povorcitinib 45 mgPovorcitinib 15 mg to 45 mgPovorcitinib 45 mgPovorcitinib 75 mg to 45 mgPlacebo to Povorcitinib 75 mgPovorcitinib 15 mg to 75 mgPovorcitinib 45 mg to 75 mgPovorcitinib 75 mg
Extension Period: Number of Participants With Any ≥Grade 3 TEAE00010133

Adverse events

Collected over from the time of Informed Consent Form signing until at least 30 days after the last dose of study drug (up to approximately 44 weeks). Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Placebo0/37 (0%)1/37 (2.7%)14/37 (37.8%)
Povorcitinib 15 mg1/36 (2.8%)2/36 (5.6%)17/36 (47.2%)
Povorcitinib 45 mg0/35 (0%)4/35 (11.4%)19/35 (54.3%)
Povorcitinib 75 mg0/37 (0%)3/37 (8.1%)22/37 (59.5%)
Placebo to Povorcitinib 45 mg0/1 (0%)0/1 (0%)0/1 (0%)
Povorcitinib 15 mg to 45 mg0/4 (0%)0/4 (0%)3/4 (75%)
Povorcitinib 45 mg to 45 mg0/8 (0%)0/8 (0%)5/8 (62.5%)
Povorcitinib 75 mg to 45 mg0/15 (0%)1/15 (6.7%)6/15 (40%)
Placebo to Povorcitinib 75 mg0/30 (0%)0/30 (0%)15/30 (50%)
Povorcitinib 15 mg to 75 mg0/25 (0%)1/25 (4%)15/25 (60%)
Povorcitinib 45 mg to 75 mg0/23 (0%)2/23 (8.7%)13/23 (56.5%)
Povorcitinib 75 mg to 75 mg0/18 (0%)3/18 (16.7%)13/18 (72.2%)
Most frequent serious events
Showing 10 of 16
Most frequent serious events
EventPlaceboPovorcitinib 15 mgPovorcitinib 45 mgPovorcitinib 75 mgPlacebo to Povorcitinib 45 mgPovorcitinib 15 mg to 45 mgPovorcitinib 45 mg to 45 mgPovorcitinib 75 mg to 45 mgPlacebo to Povorcitinib 75 mgPovorcitinib 15 mg to 75 mgPovorcitinib 45 mg to 75 mgPovorcitinib 75 mg to 75 mg
AnxietyPsychiatric disorders0/370/360/350/370/10/40/81/150/300/250/230/18
ErysipelasInfections and infestations0/370/360/350/370/10/40/80/150/300/250/231/18
HidradenitisSkin and subcutaneous tissue disorders0/370/360/350/370/10/40/80/150/300/250/231/18
MastitisInfections and infestations0/370/360/350/370/10/40/80/150/300/250/231/18
AppendicitisInfections and infestations0/370/361/350/370/10/40/80/150/300/251/230/18
COVID-19Infections and infestations0/370/360/350/370/10/40/80/150/300/251/230/18
PneumoniaInfections and infestations0/370/360/350/370/10/40/80/150/301/250/230/18
Intervertebral disc protrusionMusculoskeletal and connective tissue disorders0/370/361/350/370/10/40/80/150/300/250/230/18
Nasal septum deviationRespiratory, thoracic and mediastinal disorders0/370/361/350/370/10/40/80/150/300/250/230/18
Tooth infectionInfections and infestations0/370/361/350/370/10/40/80/150/300/250/230/18
Most frequent other events
Showing 10 of 87
Most frequent other events
EventPlaceboPovorcitinib 15 mgPovorcitinib 45 mgPovorcitinib 75 mgPlacebo to Povorcitinib 45 mgPovorcitinib 15 mg to 45 mgPovorcitinib 45 mg to 45 mgPovorcitinib 75 mg to 45 mgPlacebo to Povorcitinib 75 mgPovorcitinib 15 mg to 75 mgPovorcitinib 45 mg to 75 mgPovorcitinib 75 mg to 75 mg
Dry skinSkin and subcutaneous tissue disorders0/370/360/350/370/11/40/80/150/300/250/230/18
Ear discomfortEar and labyrinth disorders0/370/360/350/370/11/40/80/150/300/250/230/18
EpistaxisRespiratory, thoracic and mediastinal disorders0/370/360/350/370/11/41/80/152/300/250/230/18
FatigueGeneral disorders1/375/363/352/370/11/40/81/152/301/250/230/18
HypertensionVascular disorders0/370/361/350/370/11/40/80/151/301/251/231/18
NasopharyngitisInfections and infestations3/372/362/355/370/10/42/81/153/303/250/230/18
PresyncopeNervous system disorders0/370/360/350/370/11/40/80/150/300/250/230/18
Skin candidaInfections and infestations0/370/360/350/370/11/40/80/150/300/250/230/18
Upper respiratory tract infectionInfections and infestations0/371/360/350/370/11/40/80/151/301/251/230/18
Weight increasedInvestigations0/370/361/351/370/11/41/80/153/300/251/231/18

Baseline characteristics

Age, Continuous
Age, Continuous(years)PlaceboPovorcitinib 15 mgPovorcitinib 45 mgPovorcitinib 75 mgTotal
Mean52.9 ± 12.3256.0 ± 12.9255.6 ± 15.2555.9 ± 10.1855.1 ± 12.70
Sex: Female, Male
Sex: Female, Male(Participants)PlaceboPovorcitinib 15 mgPovorcitinib 45 mgPovorcitinib 75 mgTotal
Female2224272396
Male151291450
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)PlaceboPovorcitinib 15 mgPovorcitinib 45 mgPovorcitinib 75 mgTotal
Hispanic or Latino733316
Not Hispanic or Latino30323333128
Unknown or Not Reported01012
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)PlaceboPovorcitinib 15 mgPovorcitinib 45 mgPovorcitinib 75 mgTotal
White/Caucasian33312730121
Black/African-American335516
Asian02417
American-Indian/Alaska Native00011
Unknown10001
08

Study locations

49 sites
  • Investigative Site US010
    Phoenix, Arizona 85006, United States
  • Investigative Site US024
    Phoenix, Arizona 85018, United States
  • Investigative Site US001
    Fountain Valley, California 92708, United States
  • Investigative Site US014
    Sacramento, California 95816, United States
  • Investigative Site US019
    Fort Lauderdale, Florida 33308, United States
  • Investigative Site US016
    Miami, Florida 33175, United States
  • Investigative Site US013
    Miramar, Florida 33027, United States
  • Investigative Site US009
    Tampa, Florida 33609-2231, United States
  • Investigative Site 1071320
    Newnan, Georgia 30263, United States
  • Investigative Site US008
    Plainfield, Indiana 46168, United States
  • Investigative Site US011
    South Bend, Indiana 46617, United States
  • Investigative Site US003
    Baltimore, Maryland 21287, United States
  • Investigative Site US017
    Troy, Michigan 48084, United States
  • Investigative Site US006
    Saint Joseph, Missouri 64506, United States
  • Investigative Site US004
    Portsmouth, New Hampshire 03801, United States
  • Investigative Site US023
    Athens, Ohio 45701, United States
  • Investigative Site US002
    Dublin, Ohio 43016, United States
  • Investigative Site US012
    Gahanna, Ohio 43230, United States
  • Investigative Site US022
    Murfreesboro, Tennessee 37130, United States
  • Investigative Site US021
    Arlington, Texas 76011, United States
  • Investigative Site US005
    Austin, Texas 78745, United States
  • Investigative Site US018
    Dallas, Texas 75231, United States
  • Investigative Site US007
    Houston, Texas 77004, United States
  • Investigative Site CA002
    Edmonton, Alberta T6G 1C3, Canada
  • Investigative Site CA001
    Surrey, British Columbia V3R 6A7, Canada
  • Investigative Site CA004
    London, Ontario N6A 5R9, Canada
  • Investigative Site CA003
    Québec, Quebec G1W 4R4, Canada
  • Investigative Site DE007
    Bad Bentheim, 48455, Germany
  • Investigative Site DE005
    Berlin, 10117, Germany
  • Investigative Site DE004
    Bonn, 53127, Germany
  • Investigative Site DE003
    Frankfurt am Main, 60590, Germany
  • Investigative Site DE001
    Hamburg, 20246, Germany
  • Investigative Site DE002
    Münster, 48149, Germany
  • Investigative Site DE008
    Tübingen, 72076, Germany
  • Investigative Site PL005
    Kielce, 253016, Poland
  • Investigative Site PL003
    Osielsko, 86-031, Poland
  • Investigative Site PL001
    Rzeszów, 35-055, Poland
  • Investigative Site PL004
    Torun, 87100, Poland
  • Investigative Site PL002
    Wroclaw, 50-566, Poland
  • Investigative Site PR002
    Caguas, 00727, Puerto Rico
  • Investigative Site PR001
    San Juan, 00917, Puerto Rico
  • Investigative Site ES004
    Alicante, 03010, Spain
  • Investigative Site ES007
    Badalona, 08916, Spain
  • Investigative Site ES001
    Barcelona, 08036, Spain
  • Investigative Site ES002
    Córdoba, 14004, Spain
  • Investigative Site ES006
    Granada, 18014, Spain
  • Investigative Site ES008
    Madrid, 28041, Spain
  • Investigative Site ES003
    Madrid, 28223, Spain
  • Investigative Site ES005
    Valencia, 46026, Spain
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — Incyte shares data with qualified external researchers after a research proposal is submitted. These requests are reviewed and approved by a review panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations. The trial data availability is according to the criteria and process described on https://www.incyte.com/our-company/compliance-and-transparency

Supporting information: Study protocol, Statistical analysis plan

Time frame: Data will be shared after the primary publication or 2 years after the study has ended for market authorized products and indications.

Access criteria: Data from eligible studies will be shared with qualified researchers according to the criteria and process described in the Data Sharing section of the www.incyteclinicaltrials.com website. For approved requests, the researchers will be granted access to anonymized data under the terms of a data sharing agreement.

Data sharing details ↗ · www.incyte.com

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Nov 2021 to primary completion in Aug 2023, 21 months.

Results were first posted in Aug 2024, 1 year after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 20, 2021
First posted
Sep 29, 2021
StartActual
Nov 4, 2021
Primary completionActual
Aug 11, 2023
CompletionActual
Feb 28, 2024
Results first posted
Aug 27, 2024
Last update
Jul 11, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 11, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT05061693
Lead sponsor
Incyte Corporation
Responsible party
Sponsor
First posted
Sep 29, 2021
Start date
Nov 4, 2021
Primary completion
Aug 11, 2023
Completion
Feb 28, 2024
Results posted
Aug 27, 2024
Last update
Jul 11, 2025

Study contacts

Kathleen Butler, MD
study director · Incyte Corporation

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Povorcitinib

Start the discussion